申请人:Cooley Christina
公开号:US20100280219A1
公开(公告)日:2010-11-04
A cyclic carbonate monomer, including:
wherein
R
1
, R
2
, and R
3
are independently selected from the group consisting of H, linear or branched, substituted or unsubstituted alkyl;
R
10
is a connecting group selected from the group consisting of linear or branched, substituted or unsubstituted alkyl, heteroalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;
R
4
is an optional bridging group selected from the group consisting of linear or branched, substituted or unsubstituted alkyl, heteroalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;
Z is selected from the group consisting of O, NH, NR, and S;
G is a guanidine group; and
P is a protecting group.
The cylic carbonate monomer can be reacted with an initiator including a drug, drug candidate, probe or other molecule of interest to form an oligomer with the molecule of interest attached to one end of a carbonate backbone and guanidine groups attached to the carbonate backbone.
一个环状碳酸酯单体,包括:其中R1、R2和R3独立地选择自H、线性或支链、取代或未取代的烷基的组;R10是从线性或支链、取代或未取代的烷基、杂烷基、环烷基、杂环基、芳基和杂芳基中选择的连接基团;R4是可选的桥连基团,选择自线性或支链、取代或未取代的烷基、杂烷基、环烷基、杂环基、芳基和杂芳基的组;Z选择自O、NH、NR和S的组;G是一种鸟嘌呤基团;P是保护基团。环状碳酸酯单体可以与包括药物、药物候选化合物、探针或其他感兴趣分子的引发剂反应,形成一个寡聚体,其中感兴趣分子连接到碳酸酯骨架的一端,鸟嘌呤基团连接到碳酸酯骨架上。